Time from randomization until death from any cause, assessed in the intention-to-treat population, constituted the primary outcome, which was overall survival. All patients who received quizartinib or placebo, in a dose of at least one, were evaluated for safety. The ClinicalTrials.gov database includes a record of this study’s registration. The…[Read more]